Back to Search Start Over

Patient-Derived Conditionally Reprogrammed Cells in Prostate Cancer Research

Authors :
Abdalla Elbialy
Deepthi Kappala
Dhruv Desai
Peng Wang
Ahmed Fadiel
Shang-Jui Wang
Mina S. Makary
Scott Lenobel
Akshay Sood
Michael Gong
Shawn Dason
Ahmad Shabsigh
Steven Clinton
Anil V. Parwani
Nagireddy Putluri
Gennady Shvets
Jenny Li
Xuefeng Liu
Source :
Cells, Vol 13, Iss 12, p 1005 (2024)
Publication Year :
2024
Publisher :
MDPI AG, 2024.

Abstract

Prostate cancer (PCa) remains a leading cause of mortality among American men, with metastatic and recurrent disease posing significant therapeutic challenges due to a limited comprehension of the underlying biological processes governing disease initiation, dormancy, and progression. The conventional use of PCa cell lines has proven inadequate in elucidating the intricate molecular mechanisms driving PCa carcinogenesis, hindering the development of effective treatments. To address this gap, patient-derived primary cell cultures have been developed and play a pivotal role in unraveling the pathophysiological intricacies unique to PCa in each individual, offering valuable insights for translational research. This review explores the applications of the conditional reprogramming (CR) cell culture approach, showcasing its capability to rapidly and effectively cultivate patient-derived normal and tumor cells. The CR strategy facilitates the acquisition of stem cell properties by primary cells, precisely recapitulating the human pathophysiology of PCa. This nuanced understanding enables the identification of novel therapeutics. Specifically, our discussion encompasses the utility of CR cells in elucidating PCa initiation and progression, unraveling the molecular pathogenesis of metastatic PCa, addressing health disparities, and advancing personalized medicine. Coupled with the tumor organoid approach and patient-derived xenografts (PDXs), CR cells present a promising avenue for comprehending cancer biology, exploring new treatment modalities, and advancing precision medicine in the context of PCa. These approaches have been used for two NCI initiatives (PDMR: patient-derived model repositories; HCMI: human cancer models initiatives).

Details

Language :
English
ISSN :
20734409
Volume :
13
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Cells
Publication Type :
Academic Journal
Accession number :
edsdoj.9353c2c60c2643d294c8383878443da2
Document Type :
article
Full Text :
https://doi.org/10.3390/cells13121005